TY - JOUR
T1 - Activated microglia stimulate transcriptional changes in primary oligodendrocytes via IL-1β
AU - Howe, Charles L.
AU - Mayoral, Sonia
AU - Rodriguez, Moses
N1 - Funding Information:
This work was supported by grants RG3636 (CLH), RG3172 (MR), and CA1011A8 (MR) from the National Multiple Sclerosis Society, by grant NS24180 (MR) from the NIH, by funding from the MS Society of Canada (MR), by Eugene Applebaum (MR), and by Donald and Frances Herdrich (CLH). SM was supported by the Mayo Graduate School post-baccalaureate program. We thank Eric Buenz, Dr. Art Warrington, and Dr. Suresh Radhakrishnan for technical guidance during the course of this work. We thank Dr. Larry Pease, Dr. Allan Bieber, Dr. Art Warrington, and Dr. Suresh Radhakrishnan for critically reviewing the manuscript.
PY - 2006/9
Y1 - 2006/9
N2 - No therapy currently exists to repair demyelinated lesions in multiple sclerosis. However, the use of IgM antibodies may provide a valuable therapeutic avenue for evoking such repair. Unfortunately, the mechanism of immunoglobulin action in CNS repair is currently unknown but may depend upon complex interactions between multiple cell types rather than upon direct activation of a single cell type. Using rat mixed glial cultures containing oligodendrocytes, microglia, and astrocytes, we found that the Fc portion of human IgM shifts microglia to an activated phenotype, reduces glial proliferation, upregulates a variety of immediate early genes, including JunB, Egr-1, and c-Fos, and stimulates microglial production and release of IL-1β. Microglia-derived IL-1β consequently triggers transcriptional upregulation of immediate early genes such as c-Jun, Egr-1, and c-Fos in the mixed glial cultures, and stimulates the upregulation of late response genes such as lipocalin in purified oligodendrocytes. Treatment with an IL-1β receptor antagonist abrogates the effects of Fcμ on glial proliferation and prevents the upregulation of lipocalin in response to Fcμ, but does not prevent Fcμ-mediated upregulation of IL-1β, suggesting that IL-1β mediates at least some of the downstream effects of Fcμ in mixed glial cultures. We hypothesize that Fcμ-stimulated IL-1β-induced upregulation of immediate early and late response genes in oligodendrocytes may promote CNS repair.
AB - No therapy currently exists to repair demyelinated lesions in multiple sclerosis. However, the use of IgM antibodies may provide a valuable therapeutic avenue for evoking such repair. Unfortunately, the mechanism of immunoglobulin action in CNS repair is currently unknown but may depend upon complex interactions between multiple cell types rather than upon direct activation of a single cell type. Using rat mixed glial cultures containing oligodendrocytes, microglia, and astrocytes, we found that the Fc portion of human IgM shifts microglia to an activated phenotype, reduces glial proliferation, upregulates a variety of immediate early genes, including JunB, Egr-1, and c-Fos, and stimulates microglial production and release of IL-1β. Microglia-derived IL-1β consequently triggers transcriptional upregulation of immediate early genes such as c-Jun, Egr-1, and c-Fos in the mixed glial cultures, and stimulates the upregulation of late response genes such as lipocalin in purified oligodendrocytes. Treatment with an IL-1β receptor antagonist abrogates the effects of Fcμ on glial proliferation and prevents the upregulation of lipocalin in response to Fcμ, but does not prevent Fcμ-mediated upregulation of IL-1β, suggesting that IL-1β mediates at least some of the downstream effects of Fcμ in mixed glial cultures. We hypothesize that Fcμ-stimulated IL-1β-induced upregulation of immediate early and late response genes in oligodendrocytes may promote CNS repair.
KW - CNS Inflammation
KW - Demyelination
KW - Fcμ
KW - IgM
KW - Immunomodulation
KW - Interleukin-1β
KW - Neural repair
KW - Remyelination
UR - http://www.scopus.com/inward/record.url?scp=33747204588&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33747204588&partnerID=8YFLogxK
U2 - 10.1016/j.nbd.2006.06.012
DO - 10.1016/j.nbd.2006.06.012
M3 - Article
C2 - 16887357
AN - SCOPUS:33747204588
SN - 0969-9961
VL - 23
SP - 731
EP - 739
JO - Neurobiology of Disease
JF - Neurobiology of Disease
IS - 3
ER -